What are the major findmgs of the investigation? 4 0 model development stage: It is crucial to have a complete schedule and to establish the level of detail to be used prior to 3D CAD model development for the 4D model to be used according to its origmal purpose. Carrent Izinitation~ of4D CAD: Current 4D models and 4D tools are not flexible and their applicability limited. Fatare reqzlired iqbrouements: Future improvements include facilitating 4D model generation, its manipulation and relaying detected problems to users through knowledge based systems. What outputs were generated (software, other reports, video, other)? 4D model of FDC office building, this report. 6. Research Status: What is the status of the research? Completed. What is the logcal next step? Conduct further research pertaining to the h t a t i o n s described in the report. Are the results ready to be applied or do they need further development? Both. What adktional efforts are required before this research could be applied? A more detailed 4D model, improvements of current 4D tools.

No abstract

No abstract

Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levels of FGF21, FGF receptors (FGFRs), and β-klotho (KLB) were investigated in human thyroid tissues. The cell viability, migrating cells, and invading cells were measured in PTC cells after treatment with recombinant FGF21. Higher serum levels of FGF21 were found in patients with thyroid cancer than in control participants, and were significantly associated with body mass index (BMI), fasting glucose levels, triglyceride levels, tumor stage, lymphovascular invasion, and recurrence. Serum FGF21 levels were positively correlated with the BMI in patients with PTC, and significantly associated with recurrence. Recombinant FGF21 led to tumor aggressiveness via activation of the FGFR signaling axis and epithelial-to-mesenchymal transition (EMT) signaling in PTC cells, and AZD4547, an FGFR tyrosine kinase inhibitor, attenuated the effects of FGF21. Hence, FGF21 may be a new biomarker for predicting tumor progression, and targeting FGFR may be a novel therapy for the treatment of obese patients with PTC.